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 54 
Précis: In women with suspected preterm preeclampsia, a single angiogenesis-related 55 
biomarker is a useful diagnostic test to determine preeclampsia that requires delivery within 56 
14 days.  57 
  58 
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 59 
Abstract 60 
Objective: To evaluate 47 biomarkers (selected from the current medical literature), in 61 
isolation or in combination with placental growth factor (PlGF), to determine the need for 62 
delivery within 14 days, in women presenting with suspected preterm preeclampsia. 63 
 64 
Methods: In a prospective, multicentre observational study, 47 biomarkers were measured 65 
in 423 women presenting with suspected preterm preeclampsia (in two prespecified groups: 66 
Group 1 at <35 weeks of gestation and Group 2 presenting between 35+0 and 36+6 weeks of 67 
gestation), to evaluate their ability to determine the primary endpoint: preeclampsia 68 
requiring delivery within 14 days. Using factor analysis and stepwise logistic regression, we 69 
sought one or more additional biomarkers for optimal determination of the primary 70 
endpoint. 71 
 72 
Results: In women presenting <35 weeks of gestation (n=286), the best-performing 73 
combination of PlGF, podocalyxin, endoglin, procalcitonin (receiver operating curve (ROC) 74 
area 0.90; 95% CI 0.86 to 0.93) was not statistically better than PlGF alone (ROC 0.87; 95% CI 75 
0.83 to 0.92; p=0.43) for preeclampsia requiring delivery within 14 days. Two other single 76 
markers had test performance that was not significantly different to PlGF (soluble fms-like 77 
tyrosine kinase-1 [sflt-1] ROC 0.83; 95% CI 0.78 - 0.88; endoglin ROC 0.83; 95% CI 0.79 - 78 
0.88). Similar findings were found in women presenting between 35+0 and 36+6 weeks of 79 
gestation (n=137): ROC for PlGF alone 0.75 (95%CI 0.67 to 0.83); ROC for PlGF, cystatin, 80 
pregnancy-associated plasma protein A (PAPP-A) in combination 0.81 (95% CI 0.74 to 0.88; 81 
p=0.40).  82 
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 83 
Conclusions: This study supports the growing body of evidence that a single angiogenesis-84 
related biomarker (PlGF, sflt-1 or endoglin) alone represents a useful diagnostic test for 85 
women presenting with suspected preterm preeclampsia. 86 
  87 
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 88 
Introduction 89 
Preeclampsia is a common disorder affecting between 5-7% of all pregnancies.(1) It remains 90 
a major contributor to maternal mortality(1) and accounts for a substantial proportion of 91 
low birthweight infants and iatrogenic preterm delivery.(2) Prevalence and morbidity has 92 
remained unchanged over the last decade highlighting the need to improve diagnostic(3, 4) 93 
and prognostic(5) testing facilitating appropriate resource allocation. Preeclampsia is unique 94 
to pregnancy and is characterised by poor placentation(6) and abnormal inflammatory and 95 
vascular responses(7) resulting in multi-organ dysfunction.  96 
 Presenting symptoms of preeclampsia are often subjective and non-specific with 97 
clinical findings based on features of advanced disease or markers of end organ involvement. 98 
High blood pressure and urinary protein excretion are typically used to diagnose the disease 99 
but both are secondary features of a primary placental problem and subject to 100 
measurement error and poor test accuracy.(8) It is currently difficult to distinguish 101 
preeclampsia of a severity that requires early delivery from other less serious phenotypes.(9, 102 
10) An accurate biomarker (or panel of biomarkers) to enable prognosis of perinatal 103 
complications could have substantial impact on management strategies with the aim of 104 
minimising adverse maternal and fetal outcomes.   105 
 The aim of this study was to evaluate a wide panel of 47 candidate biomarkers 106 
(including those that are currently widely reported and reflect the heterogeneity of the 107 
disease) in women presenting preterm with suspected preeclampsia in order to optimise 108 
determination of an important clinical outcome, that of preeclampsia requiring delivery 109 
within 14 days.  110 
 111 
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Materials and Methods 112 
A prospective multicentre cohort study was undertaken between January 2011 and February 113 
2012 in seven consultant-led maternity units in the United Kingdom and Ireland.(4) Women 114 
were eligible for the study if they had been referred or presented with suspected 115 
preeclampsia (i.e. signs or symptoms of preeclampsia), were 20+0 to 36+6 weeks of gestation 116 
with a singleton or twin pregnancy and were aged ≥16 years. Women with confirmed 117 
preeclampsia (or with any adverse outcome already present) were not eligible. We 118 
undertook a planned analysis reported here on two groups of women: Group 1: presenting 119 
prior to 35 weeks of gestation, and Group 2: presenting between 35+0 and 36+6 weeks of 120 
gestation. These gestational age groupings were pre-specified, based on known differences 121 
in pathophysiological pathways associated with preterm pre-eclampsia and our prior 122 
knowledge of gestational changes of biomarker concentrations related to these pathways. 123 
Written informed consent was obtained and baseline demographic and pregnancy-specific 124 
information, including blood pressure readings, were entered onto the study database. 125 
Blood pressure was taken according to unit guidelines. Blood samples were drawn into 126 
ethylenediamine tetra-acetic acid, with consent, at the time of enrolment. The samples were 127 
labelled, transported to the laboratory and the plasma was stored until analysis at -80oC. 128 
Pregnancy outcomes were determined by case note review with independent adjudication 129 
(masked to all biomarker concentrations) for final maternal diagnosis. All hypertensive 130 
disorders of pregnancy were defined according to the American College of Obstetricians and 131 
Gynaecologists practice bulletin in use at the time of the study.(11) Independent 132 
adjudication was undertaken by two senior physicians, masked to biomarker measurements, 133 
requiring documentation of end points required to fulfil the diagnostic criteria; disagreement 134 
was resolved by a third adjudicator. The predefined adverse maternal outcomes had been 135 
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identified for a previous study in preeclampsia by iterative Delphi consensus(10) and have 136 
been described in detail elsewhere.(4) All sites managed women (including decision for 137 
delivery) in line with the Hypertension in Pregnancy recommendations from the National 138 
Institute for Health and Care Excellence.(12)  139 
An initial panel of biomarkers was selected based on either a priori knowledge of an 140 
association with preeclampsia, a biological role in placentation or a role in cellular 141 
mechanisms involved in the pathogenesis of preeclampsia e.g., angiogenesis, inflammation, 142 
coagulation.  The full list of 47 biomarkers, measured with 57 assays (where potentially 143 
biologically important assays of different epitope specificity were available) was generated 144 
following a review of the literature, appraisal of selected bibliographies and consultation 145 
with medical experts (Appendix 1, available online at http://links.lww.com/xxx). 146 
Plasma samples were tested for Placental Growth Factor (PlGF) using the Triage
 
PlGF Test by 147 
trained laboratory staff at the study site where the sample was taken (as previously 148 
published). Samples were labelled, and transported to the laboratory where they were spun 149 
at 3000 rotations per minute for 10 minutes. The additional 56 biomarker assays were 150 
analysed in a central laboratory facility (Alere, San Diego, CA) and full details of assay 151 
methods given in Appendix 2, http://links.lww.com/xxx and Appendix 3, 152 
http://links.lww.com/xxx. All participants had delivered and pregnancy outcomes recorded 153 
before biomarker concentrations were analysed and revealed and all laboratory staff were 154 
masked to clinical outcomes.  155 
Standard distributional checks showed high levels of skewness for all 57 assays, consistent 156 
with underlying log normal distributions. Logged values of these biomarkers were therefore 157 
used. Before considering the pregnancy outcomes, statistical factor analysis of biomarker 158 
data was undertaken, reducing the 47 biomarkers into a smaller group of factors. Factor 159 
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analysis sorted the biomarkers into a small number of highly correlated groups, without 160 
reference to outcome, containing the majority of the information in the full dataset.(13) 161 
Factor summary scores were then calculated for all women. Consideration of scree plots and 162 
Eigen-values (> two) identified the most important factors for further analysis.(14)  These 163 
factors were rotated (orthogonal varimax method) so that each factor related strongly 164 
(correlation >0.6) to a small number of biomarkers only (factor analysis is displayed in 165 
Appendix 4, http://links.lww.com/xxx). Significant factors (and their biomarkers) were 166 
identified for further investigation (Appendix 5, http://links.lww.com/xxx). For the multiple 167 
logistic regression model, the principal outcome was preeclampsia requiring delivery within 168 
14 days (pre-specified by consensus of clinical investigators). Stepwise logistic regression 169 
was used to determine which biomarkers or factors appeared to provide additional 170 
information beyond that derived from PlGF and prediction scores were extracted for the 171 
best combinations. A comparison of Receiver Operating Curves (ROC) areas of individual 172 
biomarkers and combinations was made to see if any of the additional information was both 173 
consistent and large enough to be clinically useful. Significance was assessed through use of 174 
a non-parametric test which allowed for non-independence of observations on the same 175 
participant, with Bonferroni correction for multiple testing.(15) 176 
 Some biomarkers, with high uniqueness scores, were not strongly associated with 177 
any factor. To investigate whether any of these biomarkers had diagnostic power in addition 178 
to that provided by PlGF and biomarkers identified earlier, stepwise logistic regression was 179 
undertaken. To avoid excluding a biomarker that may be of potential value, it had to pass a 180 
series of tests, so that the chance of a false positive was greatly reduced (rather than using a 181 
standard multiple-testing correction to p-values, such as Bonferroni). The biomarker had to 182 
be a component of a significant factor, a significant predictor in logistic regression both 183 
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alone and after allowing for PlGF and have a ROC area for the combined score significantly 184 
greater than PlGF alone. For biomarkers with a substantial proportion of measurements 185 
outside the limits of detection, we used a non-parametric test (ROC area) to determine 186 
whether the biomarkers had useful predictive power. Where the biomarker measurement 187 
(whether due to censoring or lack of predictive ability) was non-informative, it was excluded 188 
from further analysis.  189 
 Statistical analysis was carried out in the statistical package Stata (version 11.2), 190 
College Station Texas, USA. Clinical variables and outcomes were compared using a Wilcoxon 191 
rank-sum non-parametric test.  The pre-specified sample size was calculated for accurate 192 
estimation of the sensitivity (within 10%) and specificity (within 6%) of a biomarker, assumed 193 
a sensitivity of 0.90, specificity 0.90, and 95% confidence intervals (2-tailed), for determining 194 
the primary endpoint; this required 62 preeclampsia cases and 150 women not meeting the 195 
primary endpoint. The study is reported in accordance with STROBE guidelines (). 196 
The study was approved by East London Research Ethics Committee (ref. 10/H0701/117). 197 
Participants gave informed consent and the study followed institutional guidelines. 198 
 199 
Results 200 
Four hundred twenty three women with enrolment samples and outcome data available 201 
were recruited to the study in seven centres across the UK and Ireland between January 202 
2011 and February 2012, 286 women in Group 1 (presenting at 20+0 to 34+6 weeks of 203 
gestation) and 137 women in Group 2 (presenting at 35+0 to 36+6 weeks of gestation) (Figure 204 
1).  205 
For the 286 women who were enrolled prior to 35+0 weeks of gestation, characteristics of 206 
the study population at antenatal booking are shown in table 1, subdivided into those that 207 
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met the primary outcome (pre-eclampsia requiring delivery within 14 days) and all others. 208 
Table 2 shows characteristics of delivery and maternal and neonatal outcome. Table 3 shows 209 
the test performance for the most promising individual biomarkers, depicted by ROC areas. 210 
PIGF had the highest ROC area (0.87) for determining preeclampsia requiring delivery within 211 
14 days; the ROC areas for sflt-1 (0.83) and endoglin (0.83) were not significantly different to 212 
that for PlGF. Addition of further biomarkers to PlGF increased the ROC area by a small, non-213 
significant increment only. The highest test performance for preeclampsia requiring delivery 214 
within 14 days was found using a combination of PlGF, podocalyxin, soluble endoglin and 215 
procalcitonin, with a ROC area of 0.90, not significantly greater than the ROC area for PlGF 216 
alone (0.87; p=0.43). Appendix 6, http://links.lww.com/xxx shows ROC areas for all 47 217 
biomarkers analysed and individual median biomarker concentrations in all women sampled 218 
are shown in Appendix 7, http://links.lww.com/xxx. Sensitivity analysis demonstrated that 219 
excluding twin pregnancies altered PlGF test performance by <1%. 220 
For women presenting between 35+0 and 36+6 weeks of gestation (n=137), the characteristics 221 
at booking and enrolment are shown in Appendix 8, http://links.lww.com/xxx and those for 222 
delivery and pregnancy outcomes in Appendix 9, http://links.lww.com/xxx. ROC areas and 223 
individual median biomarker concentrations for the individual biomarkers are given in 224 
Appendix 10, http://links.lww.com/xxx and Appendix 11, http://links.lww.com/xxx, 225 
respectively. The results follow a similar pattern as for women presenting at earlier 226 
gestations. The ROC area for PlGF alone (0.75; 95% CI (0.67 to 0.83)) in determining need for 227 
delivery for preeclampsia within 14 days was lower than that achieved in earlier gestations 228 
and other angiogenesis-related biomarkers were not significantly different to that for PlGF 229 
alone. Integration of soluble fms-like tyrosine kinase-1 (sFlt-1) with PlGF (as a ratio) 230 
increased the ROC to 0.77 (95% CI 0.69 to 0.84). The combination of PlGF, pregnancy-231 
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associated plasma protein A and cystatin yielded the highest ROC area of 0.81 (95% CI (0.74 232 
to 0.88) (table 4). Both increments were small and not significant.  233 
 234 
Discussion 235 
This prospective multicentre study is a comprehensive direct comparison of diagnostic 236 
biomarkers for preeclampsia. The results demonstrate that in women with suspected 237 
preeclampsia presenting preterm, use of a single angiogenesis-related biomarker (PlGF, sflt-238 
1 or endoglin) alone represents a useful diagnostic test for determining preeclampsia 239 
requiring delivery within 14 days, a relevant endpoint indicating that a clinician has 240 
considered that the risks of adverse outcomes associated with ongoing expectant 241 
management are outweighed by the risks of delivery.  242 
 Suspected hypertensive disorders in pregnancy are the commonest reason for 243 
presentation for obstetric assessment in the third trimester of pregnancy. Diagnostic 244 
uncertainty is common when women present to obstetric assessment units with one or 245 
more signs suggestive of preeclampsia. Women undergo a series of investigations, many of 246 
which are poor predictors of the need for delivery or likely adverse outcome. In practice, 247 
obstetricians require a test that enables a woman to be triaged, to determine those that 248 
require increased surveillance, and those where the likelihood of needing delivery for 249 
preeclampsia within fourteen days is very low and outpatient care may be appropriate. Such 250 
a test would enable development of safe clinical algorithms and avoid inappropriate 251 
intervention or unnecessary maternal anxiety. 252 
 PlGF is an angiogenic factor synthesised by the trophoblast, a marker of associated 253 
placental dysfunction in preeclampsia, with known low plasma concentrations in the 254 
disease.(16) Whilst combining PlGF with some of the other 46 biologically plausible 255 
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biomarkers marginally improved the ROC area, the combinations added little to the 256 
diagnostic performance of a single biomarker alone. This important negative result 257 
demonstrates the diagnostic option of using a single biomarker (over and above a 258 
combination of biomarkers) in preterm preeclampsia. These findings are more marked in 259 
women presenting prior to 35 weeks of gestation, and are similar, with lesser diagnostic 260 
efficacy, in women presenting between 35+0 and 36+6 weeks of gestation. This probably 261 
reflects the inclusion of women who meet the primary outcome definition (preeclampsia 262 
with delivery within 14 days) who were delivered routinely at 37 weeks of gestation 263 
following national guideline recommendations and not because of a clinician concern over a 264 
potential placentally-mediated adverse event.   265 
 Strengths of this study include use of seven study sites and a large participant cohort, 266 
encompassing a wide demographic and ethnic profile including women with underlying 267 
maternal disease. Plasma testing was carried out in a central laboratory ensuring that results 268 
were obtained with rigorous quality control. Progressive statistical analysis explored single 269 
biomarker predictive power, and compared the impact of combining groups of markers, or 270 
using biomarker ratios. A limitation was that test results were not validated in a repeat 271 
sample or by comparative testing at a second laboratory.  272 
 Previous studies have described other pathophysiologically relevant third trimester 273 
markers, including soluble endoglin,(17) or measurement of a ratio such as PlGF/ soluble 274 
fms-like tyrosine kinase-1.(3, 5)  However, some of these studies have been small or from a 275 
single centre, often using a case-control design. Such study design can result in over-fitting 276 
and does not provide data indicative of how a biomarker may perform if introduced into 277 
clinical practice.  278 
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 Systematic reviews have indicated that currently utilised tests such as proteinuria,(8) 279 
transaminases(18) and uric acid(19) are not good predictors of maternal or fetal 280 
complications in women with suspected preeclampsia.  The lack of reliable diagnostic tests 281 
results in poorly targeted antenatal monitoring and hospitalisation.(20)  Development of an 282 
improved diagnostic test, using pathophysiologically relevant biomarkers may have 283 
advantages over traditional diagnostic measures.(21) A test performed at presentation that 284 
enables targeted surveillance for those at increased risk of maternal or fetal complications 285 
and provides appropriate reassurance to those who test negative has the potential to assist 286 
in the allocation of health resources.(22) Further work is also needed on prognosis of multi-287 
organ maternal complications in established preeclampsia. 288 
 Improved detection of placental disease remains a global health priority. Growing 289 
evidence suggests the use of angiogenic factors as biomarkers across a range of 290 
demographic settings in the prediction of preeclampsia,(4) adverse outcome(23) and 291 
placentally related stillbirth.(24) Previous work has shown that women with low or very low 292 
PlGF concentrations experienced adverse perinatal outcomes (4) and our findings suggest 293 
that increased surveillance should be considered for these women. 294 
We have previously reported that PlGF out-performs disease markers currently in use;(4) 295 
this study confirms that use of a single angiogenesis-related biomarker may be clinically 296 
useful as a diagnostic test, without the need for combinations (which entail additional  cost 297 
and complexity).. Biomarkers such as PlGF can be analysed quickly, representing a test that 298 
could aid risk stratification of women with suspected preterm preeclampsia. Further 299 
research, through randomised controlled trials, is essential to assess how these biomarker 300 
measurements can assist in determining (or refuting) diagnosis in preeclampsia, and how 301 
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this can improve outcomes for mother and baby through optimal tailored clinical 302 
management.  303 
 304 
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 381 
Table 1: Characteristics of participants at booking and enrolment for women presenting 382 
between 20+0 and 34+6 weeks of gestation (according to diagnosis of preeclampsia). Values 383 
given are median (quartiles) or n (%) as appropriate.  384 
Characteristics Women with 
preeclampsia 
requiring delivery 
within 14 days  
n=76 
All other 
participants 
n=210 
p value All women 
n=286 
At booking: 
Age (years) 
 
31.2 (26.8 - 35.6) 
 
32.0 (27.3 - 
35.9) 
 
0.84 
 
31.9 (27.0 - 35.8) 
Body mass index (kg/m2) 26.2 (22.8 - 30.1) 29.1 (25.0 - 
34.7) 
<0.001 28.6 (24.2 - 33.6) 
White ethnicity 50 (66) 137 (65) 0.62 187 (65) 
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Singleton pregnancy 71 (93) 203 (97) 0.27 274 (96) 
Highest first trimester 
systolic BP (mmHg) 
120 (110 - 130) 121 (110 - 130) 0.32 120 (110 - 130) 
Highest first trimester 
diastolic BP (mmHg)  
70 (65 - 80) 75 (66 - 84) 0.04 74 (66 - 81) 
Smoker at booking 11 (15) 42 (21) 0.30 58 (19) 
Quit smoking during 
pregnancy 
7 (10) 27 (13) 0.41 34 (12) 
Previous medical history:     
Preeclampsia requiring 
delivery <34 weeks 
10 (13) 20 (10) 0.20 30 (11) 
Chronic hypertension 7 (10) 38 (19) 0.08 45 (17) 
Known SLE or APS 2 (3) 10 (5) 0.44 12 (5) 
Pre-existing diabetes 
mellitus 
2 (3) 4 (2) 0.71 6 (2) 
Renal disease 5 (7) 14 (7) 0.98 19 (7) 
At enrolment:     
Gestational age at 
sampling (weeks) 
32.1 (29.5 - 33.2) 30.9 (26.3 - 
33.3) 
0.03 31.1 (28.0 - 33.4) 
New onset hypertension 53 (70) 101 (48) <0.001 154 (54) 
Worsening of 
hypertension 
14 (18) 42 (20) 0.77 56 (20) 
New onset of dipstick 57 (75) 103 (49) <0.001 160 (56) 
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proteinuria (1+ or 
greater) 
Highest systolic BP 
(mmHg) 
150 (140 - 165) 141 (129 - 156) <0.001 143 (131 - 159) 
Highest diastolic BP 
(mmHg) 
97 (88 - 102) 90 (80 - 98) <0.001 91 (82 - 100) 
Alanine transaminase 
(U/L) 
16 (12 - 21) 14 (11 - 19) 0.10 14 (11 - 20) 
Creatinine (mg/dl) 0.68 (0.57 – 0.83) 0.55 (0.48 – 
0.64) 
<0.001 0.58 (0.50 – 
0.70) 
Uric acid (mg/dl)  5.50 (4.30 - 6.89)  4.03 (3.03 - 
4.86) 
<0.001 4.32 (3.19 - 5.55) 
Platelet count (x109/l) 221 (179 - 269) 238 (204 - 274) 0.06 234 (197 - 271) 
BP: blood pressure; SLE: systemic lupus erythematosus; APS: antiphospholipid syndrome.  385 
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 387 
Table 2: Characteristics of delivery and maternal and neonatal outcome for women 388 
presenting between 20+0 and 34+6 weeks of gestation. Values given are median (quartiles) 389 
or n (%) as appropriate. 390 
Characteristics Women with 
preeclampsia 
requiring delivery 
within 14 days 
n=76 
All other 
participants 
n=210 
p value All women 
n=286 
Onset of labour     
Spontaneous 3 (4) 38 (18) 0.01 41 (14) 
Induced 13 (17) 95 (45) <0.001 108 (38) 
Pre-labour caesarean 
section 
59 (78) 75 (36) <0.001 134 (47) 
Mode of delivery     
Spontaneous 3 (4) 67 (32) <0.001 70 (25) 
Assisted vaginal delivery 4 (5) 27 (13) <0.001 31 (11) 
Caesarean section 67 (91) 116 (55) <0.001 183 (64) 
Adverse maternal 
outcome* 
37 (49) 84 (40) 0.11 121 (42) 
Gestation at delivery 
(weeks) 
32.9 (30 - 34.4) 37.9 (36 - 39.3) <0.001 36.9 (33.6 - 38.7) 
Enrolment to delivery 6.5 (3.0 – 10.0) 43.5 (25.0 – <0.001 29.5 (11.0 – 59.0) 
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interval (days) 74.0)  
Neonatal outcomes n=71 n=203  n=274 
Fetal death 3 (4) 3 (2) 0.19 6 (2) 
Neonatal death 2 (3) 0 (0) <0.001 2 (1) 
Birthweight (g) 1460  
(1030 - 1740) 
2900  
(2320 - 3350) 
<0.001 2500  
(1620 - 3170) 
Small for gestational age 
(<10th birthweight centile) 
55 (78) 75 (37) <0.001 130 (47) 
Small for gestational age 
(<3rd birthweight centile)  
49 (69) 47 (23) <0.001 96 (35) 
Small for gestational age 
(<1st birthweight centile)  
38 (54) 30 (15) <0.001 68 (25) 
Adverse perinatal 
outcome† 
34 (48) 26 (13) <0.001 60 (22) 
* Adverse maternal outcome defined as presence of any of the following complications: 391 
maternal death, eclampsia, stroke, cortical blindness or retinal detachment, hypertensive 392 
encephalopathy, systolic blood pressure ≥160mmHg, myocardial infarction, Intubation 393 
(other than for caesarean section), pulmonary oedema, platelets <50×10⁹/L (without 394 
transfusion), disseminated intravascular coagulation, thrombotic thrombocytopenic 395 
purpura/ haemolytic uraemic syndrome, hepatic dysfunction (alanine transaminase 396 
≥70IU/L), hepatic haematoma or rupture, acute fatty liver of pregnancy, creatinine >150 397 
μmol/L, renal dialysis, placental abruption, major postpartum haemorrhage, major infection. 398 
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† Adverse perinatal outcome defined as presence of any of the following complications: 399 
antepartum/ intrapartum fetal or neonatal death, neonatal unit admission for >48 hrs at 400 
term, intraventricular haemorrhage, periventricular leucomalacia, seizure, retinopathy of 401 
prematurity, respiratory distress syndrome, bronchopulmonary dysplasia or necrotising 402 
enterocolitis. 403 
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 405 
Table 3: ROC areas (95% confidence intervals) for individual biomarkers and combinations 406 
(derived from logistic regression) to determine preeclampsia requiring delivery within 14 407 
days of sampling in women presenting for women presenting between 20+0 and 34+6 408 
weeks of gestation. [ ] indicates low concentration of biomarker/ratio correlated to 409 
disease. 410 
Biomarkers or combinations ROC areas (95% 
confidence intervals)  
P value (vs. 
PlGF alone) 
[Pregnancy specific plasma protein A] (PAPP-A) 0.65 (0.57 - 0.72) <0.001 
Procalcitonin  0.65 (0.58 - 0.72) <0.001 
Neutrophil gelatinase-associated lipocalin (NGAL)  0.67 (0.61 - 0.74) <0.001 
Cystatin 0.68 (0.61 - 0.75) <0.001 
Brain natriuretic peptide (BNP) 0.75 (0.69 - 0.82) <0.001 
Interleukin-1 receptor-like 1 (ST2) 0.76 (0.85 - 0.93) <0.001 
Endoglin  0.83 (0.79 - 0.88) 0.08 
Soluble fms-like tyrosine kinase-1 (sFlt-1) 0.83 (0.78 - 0.88) 0.07 
[Placental growth factor] (PlGF) 0.87 (0.83 - 0.92) - 
Combinations   
[PlGF/sFlt-1 ratio] 0.88 (0.83 - 0.91) >0.99 
[PlGF], Tyrosine kinase (C-Met ) 0.88 (0.83 - 0.91) >0.99 
[PlGF/endoglin ratio] 0.88 (0.84 - 0.92) >0.99 
[PlGF], endoglin 0.88 (0.84 - 0.92) >0.99 
[PlGF], ST2 0.89 (0.85 - 0.93) >0.99 
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[PlGF], procalcitonin 0.89 (0.84 - 0.92) 0.86 
[PlGF], Cystatin, PAPP-A  0.89 (0.85 - 0.93) >0.99 
[PlGF], Podocalyxin, BNP, procalcitonin 0.90 (0.86 - 0.93) 0.23 
[PlGF], Podocalyxin, endoglin, procalcitonin 0.90 (0.86 - 0.93) 0.43 
 411 
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 413 
Table 4: ROC areas (95% confidence intervals) for individual biomarkers and combinations 414 
(derived from logistic regression) to determine preeclampsia requiring delivery within 14 415 
days of sampling in women presenting between 35+0 and 36+6 weeks of gestation. [ ] 416 
indicates low concentrations of biomarker correlated to disease. 417 
Biomarkers or combinations ROC areas (95% 
confidence intervals) 
P value (vs. 
PlGF alone) 
Cystatin 0.64 (0.55 - 0.73) 0.11 
[Pregnancy specific plasma protein A] (PAPP-A) 0.66 (0.58 - 0.75) 0.12 
Neutrophil gelatinase-associated lipocalin (NGAL) 0.67 (0.59 - 0.76) 0.22 
Brain natriuretic peptide (BNP) 0.70 (0.61 - 0.78) 0.35 
Interleukin-1 receptor-like 1 (ST2) 0.71 (0.63 - 0.79) 0.50 
Endoglin  0.71 (0.63 - 0.80) 0.60 
Soluble fms-like tyrosine kinase-1 (sFlt-1) 0.75 (0.67 - 0.83) 0.88 
[Placental growth factor] (PlGF) 0.75 (0.67 - 0.83)  
Combinations   
[PlGF], procalcitonin 0.73 (0.65 - 0.81) >0.99 
[PlGF], endoglin 0.75 (0.67 - 0.83) >0.99 
[PlGF], Podocalyxin, BNP, procalcitonin 0.76 (0.68 - 0.84) >0.99 
[PlGF], Podocalyxin, sEng, procalcitonin 0.76 (0.68 - 0.83) >0.99 
[PlGF/sFlt-1 ratio] 0.77 (0.69 - 0.84) >0.99 
[PlGF/endoglin ratio] 0.77 (0.66 - 0.82) >0.99 
[PlGF], Cystatin, [PAPP-A]  0.81 (0.74 - 0.88) 0.40 
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 418 
Figure legends 419 
Figure 1: Participant flow diagram 420 
